316 related articles for article (PubMed ID: 16725170)
1. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C
Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170
[TBL] [Abstract][Full Text] [Related]
2. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.
Ye L; Wen Z; Dong K; Wang X; Bu Z; Zhang H; Compans RW; Yang C
PLoS One; 2011; 6(5):e14813. PubMed ID: 21625584
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
4. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.
Zhang H; Huang Y; Fayad R; Spear GT; Qiao L
J Virol; 2004 Aug; 78(15):8342-8. PubMed ID: 15254206
[TBL] [Abstract][Full Text] [Related]
5. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
Luo M; Yuan F; Liu Y; Jiang S; Song X; Jiang P; Yin X; Ding M; Deng H
Vaccine; 2006 Jan; 24(4):435-42. PubMed ID: 16143433
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a trimeric MPER containing HIV-1 gp41 antigen.
Hinz A; Schoehn G; Quendler H; Hulsik DL; Stiegler G; Katinger H; Seaman MS; Montefiori D; Weissenhorn W
Virology; 2009 Aug; 390(2):221-7. PubMed ID: 19539967
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
9. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.
Visciano ML; Diomede L; Tagliamonte M; Tornesello ML; Asti V; Bomsel M; Buonaguro FM; Lopalco L; Buonaguro L
Vaccine; 2011 Jul; 29(31):4903-12. PubMed ID: 21596074
[TBL] [Abstract][Full Text] [Related]
10. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ
Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661
[TBL] [Abstract][Full Text] [Related]
11. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
Welman M; Lemay G; Cohen EA
Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629
[TBL] [Abstract][Full Text] [Related]
12. Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.
Ura T; Yoshida A; Xin KQ; Yoshizaki S; Yashima S; Abe S; Mizuguchi H; Okuda K
J Gene Med; 2009 Feb; 11(2):139-49. PubMed ID: 19065543
[TBL] [Abstract][Full Text] [Related]
13. Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope.
Li J; Chen X; Jiang S; Chen YH
Biochem Biophys Res Commun; 2008 Nov; 376(1):60-4. PubMed ID: 18762167
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.
Phogat S; Svehla K; Tang M; Spadaccini A; Muller J; Mascola J; Berkower I; Wyatt R
Virology; 2008 Mar; 373(1):72-84. PubMed ID: 18155743
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of immunogenicity of an HIV Env DNA vaccine by mutation of the Tyr-based endocytosis motif in the cytoplasmic domain.
Bu Z; Ye L; Vzorov A; Taylor D; Compans RW; Yang C
Virology; 2004 Oct; 328(1):62-73. PubMed ID: 15380359
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5.
Kusov YY; Zamjatina NA; Poleschuk VF; Michailov MI; Morace G; Eberle J; Gauss-Müller V
Antiviral Res; 2007 Feb; 73(2):101-11. PubMed ID: 17014915
[TBL] [Abstract][Full Text] [Related]
17. Generation of HIV-1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex.
Dawood R; Benjelloun F; Pin JJ; Kone A; Chanut B; Jospin F; Lucht F; Verrier B; Moog C; Genin C; Paul S
AIDS; 2013 Mar; 27(5):717-30. PubMed ID: 23719346
[TBL] [Abstract][Full Text] [Related]
18. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160.
Loomis LD; Deal CD; Kersey KS; Burke DS; Redfield RR; Birx DL
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):13-26. PubMed ID: 7544225
[TBL] [Abstract][Full Text] [Related]
19. Ancestral and consensus envelope immunogens for HIV-1 subtype C.
Kothe DL; Li Y; Decker JM; Bibollet-Ruche F; Zammit KP; Salazar MG; Chen Y; Weng Z; Weaver EA; Gao F; Haynes BF; Shaw GM; Korber BT; Hahn BH
Virology; 2006 Sep; 352(2):438-49. PubMed ID: 16780913
[TBL] [Abstract][Full Text] [Related]
20. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state.
Sadler K; Zhang Y; Xu J; Yu Q; Tam JP
Biopolymers; 2008; 90(3):320-9. PubMed ID: 18338371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
